| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7803931 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(9 months from now) | |
| US7579456 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(9 months from now) | |
| US10947544 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(9 months from now) | |
| US9617546 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(9 months from now) | |
| US7538211 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236773 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Nov, 2026
(2 years from now) | |
| US11491176 | ASTELLAS | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(10 years from now) | |
| US11273171 | ASTELLAS | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(10 years from now) | |
Izervay is owned by Astellas.
Izervay contains Avacincaptad Pegol Sodium.
Izervay has a total of 8 drug patents out of which 0 drug patents have expired.
Izervay was authorised for market use on 04 August, 2023.
Izervay is available in solution;intravitreal dosage forms.
Izervay can be used as treatment of geographic atrophy secondary to age-related macular degeneration by administerting avacincaptad pegol to the eye.
The generics of Izervay are possible to be released after 11 July, 2034.
Drugs and Companies using AVACINCAPTAD PEGOL SODIUM ingredient
Market Authorisation Date: 04 August, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by administerting avacincaptad pegol to the eye
Dosage: SOLUTION;INTRAVITREAL
IZERVAY family patents
